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1. Introduction
Multiple myeloma (MM) is a hematooncological disease, and in recent years, overall survival
of patients has been significantly increased. Improvement of treatment results is connected not
only to the introduction of autologous transplantation of hematopoietic cells into the treatment
strategy for younger patients in the 90s but also to the introduction of new beneficial drugs
into clinics; in the first decade of this century, bortezomib, thalidomide and lenalidomide were
introduced in [1]. These new drugs have repeatedly proven their high treatment efficacy in
clinics in all age groups of patients, in primotherapy as well as refractory disease. There are
also newer drugs currently under investigation, such as new proteasome inhibitors (carfilzo‐
mib, MLN9708 and other peroral proteasome inhibitors) and other immunomodulatory drugs
(pomalidomide) with the aim to improve or maintain treatment effects and decrease unfav‐
orable effects in [2]. Using drugs from both these groups together with glucocorticoids and
alkylating cytostatics had a major impact on prolonging survival of our patients as previously
published. On the other hand, it is clear that use of only one of the new efficient drugs in
combination with glucocorticoids and alkylating cytostatics does not lead to a cure in [3-7].
Optimization of dosage in combination with other drugs and the length of treatment have been
clarified for thalidomide and bortezomib. Current dosage levels are different from recorded
dosages in registration studies which in certain cases led to common or higher level of side
effects than is acceptable; these side effects are reduced after optimization. Side effects,
especially the long-term ones, may fundamentally influence the quality of life of patients after
successful treatment. Nowadays, optimization of thalidomide and bortezomib treatments is
almost completed and lenalidomide optimization is currently being processed in [5]. It is
logical to think that optimization of efficient drugs is a never ending process that waits for
each new efficient drug, for example carfilzomib and pomalidomide in the near future. A
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variety of new drugs are being tested in clinical studies at phases I/II. In MM treatment, modern
target therapies are being tested, such as monoclonal antibodies, kinase inhibitors or inhibitors
of other target molecules connected to one of the signaling pathways important for malignant
cells. Although treatment results of this group of drugs failed to reach expectations, we feel
that they will produce very promising results in the future. Current treatment strategies will
lead to a cure – a topic which is being discussed very seriously. In this chapter, the current
state of affairs as well as the potentials of pharmacotherapy in MM will be discussed.
2. Basic scientific data influencing current treatment strategies
Our current treatment strategies originate from a variety of research data that may be shortly
described as follows:
a. Every MM is preceded by a precancerosis called monoclonal gammopathy of undeter‐
mined significance (MGUS) in [8]. Individual stages starting from the occurrence of first
clonal plasmocyte to MGUS, MM, refractory MM up to plasmocellular leukemia are
concurrent; in one individual, they may be described as disease progression changing in
time. Many internal and external factors influence the phase when the initial plasmocyte






































MGUS, monoclonal gammopathy of undetermined significance
Figure 1. Natural history of multiple myeloma
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b. There is a variety of subtypes of multiple myeloma as this disease is very heterogenous.
Thus, MM patients have various prognoses. All currently available classifications (based
on ISS, cytogenetics, gene expression profiling, etc.) allow for classification of patients into
groups with high, low or sometimes also intermediate risk for long-term survival.
Unfortunately, no classification is specific enough to allow for prediction of treatment
success and prognosis for each individual patient in [9-11].
c. Based on the subclonal theory as well as new proofs, it seems probable that there are more
clones of plasmocytes present at the time of diagnosis in one patient. Various subclones
exist in a dynamic equilibrium, competing for limited resources with alternating domi‐
nance of various subclones at different time points. These clones have various character‐
istics including treatment sensitivity, and their ratio is significantly influenced by the
treatment given to patients. It seems that new subclones may originate even during
treatment and/or course of the disease in [12,13]. This finding has completely changed our
view of efficacy of simple combination treatments with one novel agent. On the other
hand, it is in complete harmony with important successes in the treatment including the
cure in patients treated with intensive sequences of treatment protocols consisting of most
efficient drugs. Drug combinations are essential to overcome resistance and the impact of
intra-clonal heterogeneity in [14].
d. Treatment resistance to a specific drug does not have to be absolute. From the above
mentioned subclonal theory, it is obvious that disease resistance to a certain drug in first
progression does not have to be resistant to the same drug in the fourth progression. Then,
the subclone sensitive to the drug may or may not be prevalent over resistant subclones.
In case there are no other treatment options available, it is suitable to test sensitivity to
previously used drugs.
3. Treatment strategy and treatment line
When deciding on a treatment, it is necessary to plan a complex treatment – not only anticancer
treatment but also supportive treatment; it is important to think about relapse at the time of
initial treatment, which drugs to use so that initial treatment does not block further steps in
the future. Autologous transplantation is a basic part of treatment wherever possible. Today,
treatment strategies use optimal choices of treatment lines, in an individual that should cover
5-7 disease activities within 10 years of treatment if necessary.
4. Newly diagnosed multiple myeloma
Current treatment strategies for newly diagnosed patients are always aiming to reach deepest
complete remission - molecular or immunophenotypic in [15,16]. In the first decade of this
century, therapeutic regimens with one novel agent as backbone together with glucocorticoids
and alkylating cytostatics were used as high standard based on randomized trials (Tab. 1).
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Modern protocols of second decade use intensive treatment strategies in the clinical trials
called “Multi Agent Sequential Therapy Targeting Different Clones” with at least two novel
agens based on the strong evidence of curative potential of such approaches such as Total
Therapy trials pioneered by Bart Barlogie in the Little Rock in [14].
 MPT > MP Randomized trial 6 
MPV > MP Randomized trial 1 
MPR - R > MP Randomized trial 1 
VMPT - VT > MP Randomized trial 1 
M – melfalan, P – prednison, T – thalidomide, V – Velcade (bortezomib); R – Revlimid (lenalidomide)
Table 1. Better PFS on randomized trials with one novel agent based regimen vs. melphalan prednisolon (MP)
1. Induction therapy (2-6 lines of combined therapy) in [17]
2. Myeloablative treatment (1-2 autologous transplantation)
3. Consolidation therapy (3-4 cycles of combined treatment, if possible different from entry
induction therapy) in [18,19]
4. Maintenance therapy by lenalidomide and possible combination of drugs should ensure
maintenance of remission due to probable immunomodulatory effect in [20,21].
A similar course without myeloablative regimen but with extension of the induction phase of
therapy should be evaluated for seniors not indicated for a myeloablative regimen. Unfortu‐
nately, in this group of patients, proof of curability is still anecdotal; treatment is less intensive
and more modified based on status of the patient. It is important to treat the patient and not
the disease. Adequate intensity of therapies in fragile patients is one of the more important
aspects for a final positive outcome (Tab. 2) in [22]. Novel combinative fully peroral regimens
with two novel agens will further improve prognosis in patients not indicated for myeloabla‐
tive treatment.
5. Relapse of multiple myeloma
Aims of treatment for patients with relapsed/progressed disease are more limited. Key targets
of intensive therapeutic strategies regarding the first and second relapse should be to make
the disease chronic again for several years. Balance between efficacy and toxicity as well as
long-term toxicity (peripheral polyneuropathy) are main issues in this setting in [23]. Re-
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transplantation is always one of the most effective treatment options during the relapse setting
and can be very safely used based on the individual history of the patient in [24]. There is a
reduced chance to achieve complete remission if compared to first line therapy. However,
combinative regimens using two novel agents (carfilzomib or bortezomib with lenalidomide
or thalidomide) are able to induce even higher proportions of remission including complete
remission than older types of therapy without the use of imunomodulatory drugs and
proteasome inhibitors in newly diagnosed patients (personal experience with lenalidomide
and carfilzomib). Generalized benefits for patients in further relapses from a similar number
of treatment cycles using one novel agent (IMiD or proteasome inhibitor) is in median at least
1 year in [25]. Thus, the main benefit is not due to overcoming the natural course of the disease
but rather to the possibility of using other novel agents in the next relapse. In the advanced
disease stage, the treatment is very individualized and reaches a state of stability for a longer
period of time (> 6 months) is considered to be acceptable treatment outcome. Long term
survival of more than 10 years is currently reached for more than one third of multiple
myeloma patients; this has been achieved due to new efficient drugs that can be offered to
patients in relapse. It is important to create long-term treatment strategies so that the patient
is offered efficient treatment even in third, fourth and further relapses of the disease. The
patients who have relapsed after at least two new drugs have a very poor outcome if no other
new drug is available, and they should receive the best palliative care in [26].
Agent Dose level 0 Dose level -1 Dose level -2
Dexamethasone 40 mg/dd 1,8,15,22 / 4 wk
20 mg/d
d 1,8,15,22 / 4 wk
10 mg/d
d 1,8,15,22 / 4 wk
Melphalan 0.25 mg/kgd 1-4 / 4-6 wks
0.18 mg/kg
d 1-4 / 4-6 wks
0.13 mg/kg
d 1-4 / 4-6 wks
Prednisone 50 mg qod 25 mg qod 12.5 mg qod
Cyclophosphamide 100 mg/dd 1-21 / 4 wks
50 mg/d
d 1-21 / 4 wks
50 mg qod
d 1-21 / 4 wks
Bortezomib 1.3 mg/m
2 twice/wk
d 1,4,8,11 / 3 wks
1.3 mg/m2 once/wk
d 1,8,15,22 / 5 wks
1.0 mg/m2 once/wk
d 1,8,15,22 / 5 wks
Thalidomide 100 mg/d 50 mg/d 50 mg qod
Lenalidomide 25 mg/dd 1-21 / 4 wks
15 mg/d
d 1-21 / 4 wks
10 mg/d
d 1-21 / 4 wks
Wk, week; d, day; qod, every other day
Adopted from Palumbo & Anderson, New Engl J Med 2011
Table 2. Dose reductions algorithm for frail patients
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6. Drugs available for intensive treatments
It is necessary to note that novel agents, imunomodulatory drugs (thalidomide, lenalidomide,
pomalidomide) and proteasome inhibitors (bortezomib, carfilzomib), are key players currently
used in therapeutical protocols and/or in the clinical trials. The ’old’ drugs, such as alkylating
cytostatics and glucocorticoids, still belong to the most effective group of drugs in multiple
myeloma. These old drugs are used in most treatment protocols. The therapeutic strategy in
newly diagnosed patients is described in details in another chapter (Induction Therapy in
Multiple Myeloma). The same drugs could be used in a relapse setting depending on the
components of initial therapy, efficacy and toxicity of the initial therapy, patient status and
circumstances of relapse (age, performance status, glucose metabolism, aggressive vs non-
aggressive relapse, bone marrow reserve, renal function impairment, pre-existing peripheral
neuropathy and quality of life considerations).
7. Drugs available for the maintenance part of treatment regimen
Decade after decade, there is a change in opinion about benefits of maintenance therapy. While
conventional cytostatics and glucocorticoids were used because of lack of any other option,
the era of interferon alpha ended with the introduction of immunomodulatory drugs. It is also
true that worldwide, interferon alpha had never been accepted as routine maintenance therapy
because of its comparatively high toxicity as well as minimal benefit for the unclassified
subgroup of patients in [28].
8. Immunomodulatory drugs (IMiDs)
Meta-analysis of randomized clinical studies of phase III with thalidomide as maintenance
therapy confirms the benefits of use after autologous transplantation. Statistically significant
increase of PFS in six studies and overall survival prolongation in three studies were noted.
On the other hand, only one third of patients tolerated thalidomide maintenance therapy for
more than a year. At this point, when there are less toxic drugs available for maintenance
therapy, thalidomide is recommended as a part of short-term intensive consolidation therapies
in [29,28,30].
Lenalidomide was tested in two independent randomized clinical trials of phase III as
maintenance treatment after autologous transplantation. Both these trials, CALGB 100104 and
IFM 2005-02, demonstrated benefit from lenalidomide compared to placebo, which showed a
major decrease in risk of progression by 60% in [21] and an improvement of three-year PFS in
the group with lenalidomide (61% vs. 34%) in [20]. Based on new analyses (follow-up of 28
months), there was a statistically significant improvement in overall survival in Len/Dex
treated groups of patients in comparison to the placebo treated group of patients, regardless
of short follow-ups in [21]. Its role in maintenance therapy is highlighted by improved results
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when RMP-R treatment is used with maintenance therapy compared to RMP without main‐
tenance therapy in a study of seniors MM-015 in [31]. RMP-R treatment ensured one of the
longest median of PFS (31 months). Maintenance therapy of lenalidomide was generally well
tolerated with no signs of cumulative toxicity as in the case of thalidomide. Although the
occurrence of secondary malignancies after lenalidomide treatment was increased, the risk of
disease progression or death by MM overcame this risk in [5]. Despite superb results of
maintenance therapy by lenalidomide, it is not yet approved for maintenance therapy till the
end of the year 2012 mainly due to safety reasons, although long-term results are also limited.
9. Inhibitors of proteasomes
In the study GEM/Pethema, patients were induced by VMP (bortezomib, melphalan, predni‐
solon) or VTP (bortezomib, thalidomid, prednisolon) and randomized for maintenance
treatment (VT or VP) for 3 years. Maintenance treatment with bortezomib increased IF-CR
from 24% to 42% in [32]. Maintenance treatment with bortezomib was better after autologous
transplantation in comparison to thalidomide (PFS 28 vs. 35 months; p=0.002), and overall
survival benefit was seen not only for the whole group (p = 0.049) but also for high risk patients
in [33]. So far, there is not enough information about maintenance therapy with bortezomib
although the data are promising. The change in the route of bortezomib administration from
intravenous to subcutaneous significantly reduced toxicity, mainly peripheral polyneurop‐
athy in [34]. Thus, long-term use of bortezomib will be more suitable for patients starting at
the end of the year 2012. Moreover, novel proteasome inhibitors that undergo clinical trials
have limited toxicity and per oral route of administration that further increased their potential
for maintenance therapy in [35].
10. Curability of available treatment options
Multiple myeloma is curable if an intensive combination regime is used upfront. Long-term
complete remission becomes a more important factor than reaching complete remission.
Complete remission that lasts more than three years is the first milestone on the road towards
curability in [36]. It is necessary to accentuate that in the light of current knowledge and long-
term experience with intensive regimens, the possibility of curing MM patients is being
discussed from the end of 2011 in [37]. The first report, at the time very provocative, was
presented at ASH in 2009 suggesting the possibility of a cure in 2009 in [29]. This was a major
breakthrough in the observation of this malignant disease.
Which MM patients have a chance of a cure and what is that chance? Curability depends on
reaching a deep and constant complete remission which is most probable and possible in MM
patients with a favorable prognosis suitable for autologous transplantation. Of which are
treated by an intensive combination treatment composed of the most effectively available
drugs. These drugs are set into a complex block of entry induction therapy followed by
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maintenance therapy. Curability is possible only in patients with a low-risk based on gene
expression profiles and cytogenetics based on experience from Total Therapy 3 treatment
protocols in [30]. It is important to realize how many patients really have this chance. Of all
MM patients, about 40% are involved in intensive treatments. Out of these patients, about 80%
are low risk which means about 32% of entry number. To simplify the calculation, about 75%
of these patients reach complete remission (24% of entry numbers), and up to 85-90% of these
patients reach long-term complete remission (21% of entry numbers) with a chance of cura‐
bility at about 50-60% (10-12% of entry numbers) in [29,36,30]. Thus, based on available data,
a qualified estimate would suggest that a chance for cure is possible for 10% of MM patients
and 25% of patients who are able to undergo intensive treatments including myeloablation.






























Figure 2. Natural history of multiple myeloma can be changed
11. Summary
In 2012, we can announce MM to be a curable disease under favorable prognostic conditions
at the time of diagnosis and using intensive therapy in about 10% of MM patients. Relapsed
MM or disease progression is not curable using current treatment options with the exception
of allogeneic transplants in some cases. Due to highly efficient drugs, especially proteasome
inhibitors and immunomodulatory drugs, our current treatment options are such that we can
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modulate another 5-6 active parts of the disease and offer long-term survival of more than 10years to more than 1/3 of the patients.
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